Key Highlights
- Evolent targets automating more than 80% of manual prior-authorization cases by 2027.
- Third-quarter Revenue was $725.4 million, up from $479.5 million a year earlier.
- The medical expense ratio rose to 93.0% from 85.0%.
- Management raised 2026 adjusted EBITDA guidance to $130 million to $135 million.
Evolent Health, Inc (NYSE:EVH) is increasingly framing its Margin story around automation rather than pricing alone. On its November 5 third-quarter call, management said its AuthIntelligence platform had moved from pilot to broad deployment and that it expects to target more than 80% of manual prior-authorization cases for automation by 2027. For a specialty-care manager whose adjusted EBITDA margin compressed to 4.7% in the quarter, the pace at which artificial intelligence lowers clinical review costs could become one of the more closely watched variables heading into 2027 planning.
Latest Company Context
Evolent reported third-quarter 2026 revenue of $725.4 million, up from $479.5 million a year earlier, according to its November 5 release. Adjusted EBITDA was $34.3 million, versus $39.0 million, and the net loss attributable to common shareholders narrowed to $23.6 million from $26.9 million. Adjusted income per share was $0.06. The medical expense ratio rose to 93.0% from 85.0%, reflecting the heavier weight of risk-based Performance Suite arrangements. Management reiterated 2026 revenue guidance of $2.6 billion to $2.7 billion and raised adjusted EBITDA guidance to $130 million to $135 million, with capital expenditures expected at $26 million to $28 million. Market data reported that shares traded at $4.55 after the release, down from $4.80 beforehand, implying a Market Value of about $513 million.
Key Business and index Drivers
according to market data, AuthIntelligence now processes roughly one million cases a year and has raised auto-authorization rates by up to 20 percentage points in targeted specialties. That matters because utilization review in oncology, cardiology and musculoskeletal care is labor intensive; automating a larger share of routine requests could lower the cost of each case and speed decisions for providers. Market data also noted that coverage with one national payer expanded into 11 more states, bringing that client to roughly 7 million lives, which could enlarge the pool of cases flowing through automated review.
Management said it expects AI-driven cost reductions to start producing returns in late 2027, while AI-related capital spending is expected to rise in 2027. That sequencing creates a timing gap: spending may arrive before savings.
What Investors Should Watch
The next major data point is fourth-quarter and full-year 2026 results, expected in early 2027 based on the company's usual calendar, though a date has not been announced. Investors may watch for 2027 guidance on capital expenditures, since management signaled higher AI-related investment. Updates on auto-authorization rates, case volumes handled without manual review, and any change to the 2027 automation target could indicate whether the program is on schedule.
Separately, Evolent has said it intends to deploy up to $50 million to reduce Debt by year-end, against $969.5 million of long-term debt and $148.3 million of cash at September 30. Policy is another variable: management said current guidance assumes no major Medicaid or exchange regulatory changes. Investors may also track whether recent expansions, including a four-year extension with the largest Surgical Management customer, are serviced with fewer manual reviews.
Automation Payoff Still Ahead
Evolent's AI program has moved from concept to operating scale, but the financial payoff is, by management's own timeline, still more than a year away. In the meantime, a 93% medical expense ratio and thin EBITDA margins leave limited room for execution slips. Whether automation can lift margins as projected may depend on adoption across specialties, the level of 2027 capital spending and customer acceptance of faster, machine-assisted decisions. Upcoming guidance could provide more clarity on that trade-off.


_11_18_2026_12_50_29_022597.jpg)



Please wait processing your request...